Innoviva (INVA)
(Delayed Data from NSDQ)
$18.90 USD
-0.01 (-0.05%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $18.91 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum C VGM
Fundamental Charts
About Free Cash Flow (Quarterly)
The Company's quarterly Free Cash Flow is a measure of financial performance and represents the cash that a company is able to generate after factoring the money required to maintain or expand its asset base. Free cash flow is important because it allows a company to pursue opportunities that enhance shareholder value. Free Cash Flow is net income + plus depreciation and amortization - capital expenditures. A higher number is considered better.
INVA 18.90 -0.01(-0.05%)
Will INVA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INVA
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
Is Innoviva (INVA) Stock Undervalued Right Now?
INVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
Other News for INVA
IHF: Healthcare Dashboard For September
Biotech Alert: Searches spiking for these stocks today
Innoviva to Participate in Upcoming Investor Conferences
Innoviva's Rollercoaster: Critical Care Bets With Respiratory Backing
IXJ: Healthcare Sector Dashboard For August